LOX and Hepatic fibrosis: LOX and LOXL inhibition by the non-selective inhibitor BAPN decreased liver stiffness and liver HSC/myofibroblast activation, paralleled by a reduction in the number of α-SMA positive cells in rodent models of liver fibrosis.11